Fosun shares suffer as $1.3 billion Gland takeover hits Himalayan roadblock

3 August 2017
mergers-acquisitions-big

The Cabinet Committee on Economic Affairs of India (CCEA) has decided to block Shanghai Fosun Pharmaceutical’s (HK: 02196) 8.5 billion yuan ($1.3 billion) takeover of the Indian drugmaker Gland Pharma, according to reports.

Bloomberg reported the news on Monday, and since then Fosun’s share price has dropped by 2% to HK$27.10 in Hong Kong.

It was more than a year ago when the agreement for Fosun to buy an 86% stake in the Indian injectables company backed by American investment company KKR.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics